source
- T-Therapeutics secures $133 million Series B to advance bispecific cancer and autoimmune drugsT-Therapeutics, a UK-based biotech focused on T-cell engager technology, announced a $133 million Series B financing. The capital will be used to generate proof-of-concept data for its lead bispec…
- Alethio Therapeutics secures $90 million to develop treatments for rare blood cancersAlethio Therapeutics, a UK based biotechnology startup, announced it has raised $90 million in new financing. The capital will be used to advance its pipeline targeting myeloproliferative neoplasm…